ArticleCVIR endovascular2025
Bronchial artery embolization for the treatment of hemoptysis: permanent versus temporary embolic materials, a single center study.
Article in CVIR endovascular, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Predictors of Recurrence Following Bronchial Artery Embolisation (BAE) for Haemoptysis: A Systematic Review and Evidence Synthesis Analyses Using SWiM Guidelines.Cardiovascular and interventional radiology · 2026Pooled it
- Bronchial Artery Embolisation in Haemoptysis Management: A Scoping Review with Emphasis on Embolic Materials and Indications.Advances in respiratory medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBronchial artery embolization (BAE) is a common interventional radiology technique used to control significant bleeding from the bronchial circulation, especially in cases of severe hemoptysis or pulmonary hemorrhage. The choice of embolizing agents plays a key role in the success, recurrence of bleeding, and safety of the procedure. However, there is no consensus on the ideal embolizing agent. This study compares the efficacy, safety, and long-term outcomes of using permanent versus temporary embolizing agents in BAE.
methodsThis retrospective cohort study included patients who underwent BAE at our institution from July 2006 to May 2024. Inclusion criteria encompassed patients with hemoptysis requiring intervention, complete clinical and radiological data, and BAE with either permanent (e.g., coils, PVA particles) or temporary (e.g., gelatin sponge) embolic materials. Exclusion criteria included non-bronchial causes of hemoptysis, BAE as part of a lung transplant protocol, or use of combined embolic materials. Primary outcomes included early clinical success (cessation of bleeding during the procedure and no recurrence within a week) and late clinical success (no bleeding recurrence within 6 months). Secondary outcomes focused on procedural complications, such as pneumonia, lung infarction, or bronchial ischemia.
resultsThis retrospective study included a total of ninety-four procedures performed in eighty-five patients (56 males, 29 females; mean age 59; age range 8-92 years) who were admitted for BAE between July 2006 and May 2024. Permanent embolic materials were used in 59 procedures (64%), in most cases were used particles and glue (39% and 21%, respectively), while temporary embolizing materials (gelatin sponge) were used in 35 procedures (37%). Statistical analysis showed a superiority in terms of clinical outcomes in favor of permanent embolic materials (p-value 0,047).
conclusionsBAE is a safe procedure for control of hemoptysis of varying etiologies and possesses high rates of immediate clinical success with few complications. In terms of embolic materials, a superiority in term of late clinical success and lower hemorrhage recurrency rate with permanent materials were clearly observed in our population, with a similar safety profile. Further studies are needed to confirm our findings and strengthen evidence.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.